NCT00058539View on ClinicalTrials.gov

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Prostate Cancer
Interventions
DRUG

rhuMAb 2C4 (pertuzumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY